Shenyang Xingqi Pharmaceutical (300573.SZ): Beimeiquanlisu eye drops received drug registration certificate.
Xingqi Eye Medicine (300573.SZ) announced that the company has received the "Drug Registration Certificate" for Bemiprost eye drops issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). This product is a eye drop with Bemiprost as the active ingredient, with two approved specifications: 0.03% (0.4ml: 0.12mg) single-dose eye drops without preservatives, and 0.03% (3ml: 0.9mg) multi-dose eye drops. Both specifications are indicated for reducing intraocular pressure in patients with angle-closure glaucoma and ocular hypertension.
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company has received the "Drug Registration Certificate" for Bemiprost Eye Drops approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). This product is an eye drops containing Bemiprost as the active ingredient, with two approved specifications: 0.03% (0.4ml: 0.12mg) single dose eye drops without preservatives and 0.03% (3ml: 0.9mg) multi-dose eye drops. Both specifications are indicated for lowering eye pressure in patients with open-angle glaucoma and ocular hypertension.
Related Articles
On May 21, KINGDEE INT'L (00268) spent HKD 11.3046 million to repurchase 1.492 million shares.
Bank of China (03988) completes the issuance of 2026 non-capital bonds for absorbing total loss absorption capacity (first tranche) (BondsLink)
Midea Group Co., Ltd (00300) spent 101 million yuan on May 21 to repurchase 1.23 million shares of A-shares.
On May 21, KINGDEE INT'L (00268) spent HKD 11.3046 million to repurchase 1.492 million shares.
Bank of China (03988) completes the issuance of 2026 non-capital bonds for absorbing total loss absorption capacity (first tranche) (BondsLink)
Midea Group Co., Ltd (00300) spent 101 million yuan on May 21 to repurchase 1.23 million shares of A-shares.
